Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes
September 13, 2022 08:02 ET
|
Novome Biotechnologies, Inc.
- Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease - - Financing includes new investors led by...
Novome Biotechnologies Appoints Bill McLeod as Chief Financial Officer
October 20, 2021 09:02 ET
|
Novome Biotechnologies, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today...
Novome Biotechnologies Initiates Phase 1/2a Study to Evaluate Therapeutically Engineered Bacteria for the Treatment of Enteric Hyperoxaluria
June 30, 2021 09:00 ET
|
Novome Biotechnologies, Inc.
- NOV-001 is the first therapeutically engineered colonizing gut bacteria to be evaluated in humans - - Phase 1 results anticipated in 2021 and Phase 2a preliminary efficacy results in 2022 - SOUTH...
Novome Biotechnologies Appoints Dr. Lachy McLean as Chief Medical Officer
June 22, 2021 08:00 ET
|
Novome Biotechnologies, Inc.
SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today...
Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors
May 26, 2021 10:00 ET
|
Novome Biotechnologies, Inc.
SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced...